Skip to content

Independently developed high-voltage steep pulse therapeutic apparatus in the treatment of hepatoma: a randomized controlled trial

Self-developed high voltage and steep pulse therapeutic apparatus in the treatment of hepatic solid tumors: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017516
Enrollment
Unknown
Registered
2020-08-02
Start date
2018-08-15
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Experimental group:High Voltage Steep Pulse Ablation

Sponsors

Chinese PLA General Hostital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-70 years, male or female; (2) The diagnosis of HCC or other cancers with hepatic metastatic with CT scan or dynamic contrast enhanced MRI; (3) tumor size must be=4cm,There are at least one tumor, but less than or equal to 3 tumors; (4) Eastern Cooperative Oncology Group (ECOG) score of 0-2; (5) Life expectancy of at least 6 months; (6) Prior Informed Consent Form.

Exclusion criteria

Exclusion criteria: (1) accompanied by severe infectious diseases such as bacteremia and toxemia; (2) people with severe coagulation dysfunction; (3) people with serious heart, brain, lung and other diseases; (4) any active implanted device (eg pacemakers or defibrillators, electronic devices and metal parts); (5) patients with a history of epilepsy; (6) patients with arrhythmia; (7) patients with acute myocardial infarction within 6 months; (8) women who are pregnant and lactating women or women of child-bearing potential who are not using an acceptable method of contraception; (9) have received treatment with an investigational agent/ procedure within 30 days; (10) the researchers believe that there are any other factors that are not suitable for inclusion in the study or that affect the participants' participation in the study.

Design outcomes

Primary

MeasureTime frame
CT;Temperature;Blood Pressure;

Countries

China

Contacts

Public ContactXiao Yueyong

General Hospital of PLA

xiaoyueyong@126.com+86 13911710987

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026